Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

MYCN regulates oncogenic MicroRNAs in neuroblastoma.

Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B.

Int J Cancer. 2008 Feb 1;122(3):699-704.

2.
3.

The MYCN oncoprotein as a drug development target.

Lu X, Pearson A, Lunec J.

Cancer Lett. 2003 Jul 18;197(1-2):125-30. Review.

PMID:
12880971
4.

N-myc and noncoding RNAs in neuroblastoma.

Buechner J, Einvik C.

Mol Cancer Res. 2012 Oct;10(10):1243-53. doi: 10.1158/1541-7786.MCR-12-0244. Epub 2012 Aug 30. Review.

5.

MYCN oncoprotein targets and their therapeutic potential.

Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA.

Cancer Lett. 2010 Jul 28;293(2):144-57. doi: 10.1016/j.canlet.2010.01.015. Epub 2010 Feb 13. Review.

PMID:
20153925
6.

MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.

Slack A, Lozano G, Shohet JM.

Cancer Lett. 2005 Oct 18;228(1-2):21-7. Review.

PMID:
15927364
7.

Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.

Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B.

BMC Cancer. 2007 May 25;7:89. Review.

8.

MYCN, neuroblastoma and focal adhesion kinase (FAK).

Beierle EA.

Front Biosci (Elite Ed). 2011 Jan 1;3:421-33. Review.

9.

Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'.

van Noesel MM, Versteeg R.

Gene. 2004 Jan 21;325:1-15. Review.

PMID:
14697505
10.

MYCN in neuronal tumours.

Schwab M.

Cancer Lett. 2004 Feb 20;204(2):179-87. Review.

PMID:
15013217
11.

Nitric oxide control of MYCN expression and multi drug resistance genes in tumours of neural origin.

Porro A, Chrochemore C, Cambuli F, Iraci N, Contestabile A, Perini G.

Curr Pharm Des. 2010;16(4):431-9. Review.

PMID:
20236072
12.

The Three Paralogous MicroRNA Clusters in Development and Disease, miR-17-92, miR-106a-363, and miR-106b-25.

Khuu C, Utheim TP, Sehic A.

Scientifica (Cairo). 2016;2016:1379643. doi: 10.1155/2016/1379643. Epub 2016 Apr 4. Review.

13.

Perspectives on neuroblastoma.

Carachi R.

Pediatr Surg Int. 2002 Sep;18(5-6):299-305. Epub 2002 Jul 24. Review. No abstract available.

PMID:
12415343
14.

More than the genes, the tumor microenvironment in neuroblastoma.

Borriello L, Seeger RC, Asgharzadeh S, DeClerck YA.

Cancer Lett. 2016 Sep 28;380(1):304-14. doi: 10.1016/j.canlet.2015.11.017. Epub 2015 Nov 17. Review.

PMID:
26597947
15.

The MYCN Protein in Health and Disease.

Ruiz-PĂ©rez MV, Henley AB, Arsenian-Henriksson M.

Genes (Basel). 2017 Mar 30;8(4). pii: E113. doi: 10.3390/genes8040113. Review.

16.

MYC in Regulating Immunity: Metabolism and Beyond.

Gnanaprakasam JN, Wang R.

Genes (Basel). 2017 Feb 25;8(3). pii: E88. doi: 10.3390/genes8030088. Review.

17.

An Introspective Update on the Influence of miRNAs in Breast Carcinoma and Neuroblastoma Chemoresistance.

Carta A, Chetcuti R, Ayers D.

Genet Res Int. 2014;2014:743050. doi: 10.1155/2014/743050. Epub 2014 Dec 4. Review.

Supplemental Content

Support Center